ERBB2 and breast cancer: Triple negative BC (TNBC), accounting for about 15% of BC and characterized by negativity for Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2, is associated with aggressive histology, poor prognosis, and unresponsiveness to the usual endocrine therapies [4–6].